{"nctId":"NCT02955329","briefTitle":"Vaping THC From Electronic Cigarettes","startDateStruct":{"date":"2019-03-20","type":"ACTUAL"},"conditions":["Marijuana Dependence"],"count":8,"armGroups":[{"label":"Tobacco Arm","type":"EXPERIMENTAL","interventionNames":["Drug: Nicotine","Device: PAX Loose Leaf Vaporizer"]},{"label":"Cannabis Arm","type":"EXPERIMENTAL","interventionNames":["Drug: Cannabis","Device: PAX Loose Leaf Vaporizer"]},{"label":"Combined Cannabis and Tobacco Arm","type":"EXPERIMENTAL","interventionNames":["Drug: Nicotine","Drug: Cannabis","Device: PAX Loose Leaf Vaporizer"]}],"interventions":[{"name":"Nicotine","otherNames":["Tobacco Leaf"]},{"name":"Cannabis","otherNames":["Marijuana Leaf"]},{"name":"PAX Loose Leaf Vaporizer","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion\n\n* Age \\>=21 years \\<=70 years\n* Regular user of tobacco cigarettes (daily or most days)\n* Regular user of cannabis in any form (combusted or ingested) at least 5 days out of the month.\n* Positive for Tetrahydrocannabinol (THC) on screening toxicology test\n* Willing to abstain from tobacco smoking and all other combustible products (ex: cigars) for 12 hours prior to each outpatient hospital admission.\n* Willing to abstain from smoking/ingesting cannabis for 12 hours prior to each outpatient hospital admission.\n* Willing to abstain from using any kind of nicotine products for 12 hours prior to each outpatient hospital admission (ex: electronic cigarettes, nicotine replacement therapy).\n* Saliva cotinine ≥ 30 ng/mL and/or NicAlert of 6\n* Healthy (based on limited physical examination and medical history collected during screening)\n* Heart rate \\< 105 beats per minute (BPM)\n* Systolic Blood Pressure \\< 160 and \\> 90 (considered out of range if both machine and manual readings are above/below these thresholds)\n* Diastolic Blood Pressure \\< 100 and \\> 50 (considered out of range if both machine and manual readings are above/below these thresholds)\n* Body Mass Index ≤\\<=38.0\n\nExclusion\n\n* Medical (The following unstable medical conditions):\n* Heart disease\n* Uncontrolled hypertension\n* Thyroid disease (okay if controlled with medication)\n* Diabetes\n* Hepatitis B or C or Liver disease\n* Glaucoma\n* Prostatic hypertrophy\n* History of paranoia after marijuana use\n* Psychiatric conditions\n* Current or past schizophrenia, and/or current or past bipolar disorder\n* Adult onset Attention-deficit/hyperactivity disorder (ADHD) (if being treated)\n* Participants with current or past depression and/or anxiety disorders will be reviewed by the study physician and considered for inclusion\n* History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per study physician's approval\n* Drug/Alcohol Dependence\n* Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program and are currently abstaining from drug and alcohol\n* Positive toxicology test at the screening visit (THC \\& prescribed medications okay)\n* Methadone replacement therapy\n* Scoring a 2 or higher on the Severity of Dependence Scale for cannabis use.\n* Psychiatric medications\n* Current regular use of any psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitors (SSRIs) and serotonin-norepinephrine reuptake Inhibitors (SNRIs) and current evaluation by the study physician that the participant is otherwise healthy, stable, and able to participate.\n* Other Medications\n* Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, dexamethasone, phenobarbital, and other anticonvulsant drugs).\n* Concurrent use of nicotine-containing medications\n* Other/Misc. Chronic Health Conditions\n* Oral thrush\n* Fainting\n* Untreated thyroid disease\n* Other \"life threatening illnesses\" as per study physician's discretion\n* Use of Other Tobacco Products (OTP); any of the following products in combination more than 15 times in the past month\n* smokeless tobacco\n* pipes\n* cigars, cigarillos\n* blunts, spliffs\n* Pregnancy\n* Pregnancy (self-reported and urine pregnancy test)\n* Breastfeeding (determined by self-report)\n* Concurrent participation in another clinical trial\n* Inability to communicate in English\n* Planning to quit smoking or cannabis use within the next 60 days","healthyVolunteers":true,"sex":"ALL","minimumAge":"21 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Delivered and Retained Doses","description":"Delivered Tetrahydrocannabinol (THC) and nicotine doses are estimated as the change in e-cigarette weight × concentration of THC or nicotine in e-liquid. The amount of THC or nicotine systemically retained is estimated as delivered dose minus amount in gas traps.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.016","spread":"0.003"},{"groupId":"OG001","value":"0.018","spread":"0.008"},{"groupId":"OG002","value":"0.026","spread":"0.008"}]}]}]},{"type":"PRIMARY","title":"Median Peak THC Concentration (Cmax)","description":"Median peak concentration of THC between vaped loose-leaf cannabis, mixture of cannabis and tobacco containing nicotine, and the tobacco alone treatment condition will be reported","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.52","spread":null},{"groupId":"OG001","value":"9.72","spread":null},{"groupId":"OG002","value":"25.74","spread":null}]}]}]},{"type":"PRIMARY","title":"Median Peak Nicotine Concentration (Cmax)","description":"Median peak concentration of nicotine between vaped loose-leaf cannabis, mixture of cannabis and tobacco containing nicotine, and the tobacco alone treatment condition will be reported","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","spread":null},{"groupId":"OG001","value":"0.38","spread":null},{"groupId":"OG002","value":"1.59","spread":null}]}]}]},{"type":"PRIMARY","title":"Median THC Exposure","description":"Median exposure of nicotine using area under the blood/plasma concentration-time curve(AUC) between vaped loose-leaf cannabis, mixture of cannabis and tobacco containing nicotine, and the tobacco alone treatment condition will be reported","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"201.6","spread":null},{"groupId":"OG001","value":"306.4","spread":null},{"groupId":"OG002","value":"585.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Median Nicotine Exposure","description":"Compare median exposure of nicotine using AUC (area under the blood/plasma concentration-time curve) between vaped loose-leaf tobacco containing nicotine vs. mixture of cannabis and tobacco containing nicotine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.1","spread":null},{"groupId":"OG001","value":"42.7","spread":null},{"groupId":"OG002","value":"134.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Heart Rate","description":"Heart rate monitoring by pulse oximeter","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.3","spread":null},{"groupId":"OG001","value":"66.8","spread":null},{"groupId":"OG002","value":"70.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Score on the Drug Effects Questionnaire (DEQ)","description":"The Drug Effects Questionnaire (DEQ) is widely used in studies of acute subjective response (SR) to a variety of substances which assessed the extent to which participants (1) feel any substance effect(s), (2) feel high, (3) like the effects, (4) dislike the effects, and (5) want more of the substance by instructing participants to place a mark on a 100mm vertical, visual, analog scale with scores ranging from 0 =\"not at all\" to 100 = \"extremely\" for each question. The mean of the individual responses is used to general a total score with a range from 0 to 100, with higher scores indicate a greater \"liking\" of the effects of the substance. The mean and standard deviation of each treatment condition will be reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.4","spread":"33.7"},{"groupId":"OG001","value":"69.0","spread":"16.7"},{"groupId":"OG002","value":"73.2","spread":"14.4"}]}]}]},{"type":"PRIMARY","title":"Mean Scores on the Marijuana Craving Questionnaire-Short Form (MCQ-SF)","description":"This 12-item multidimensional measure assesses cannabis craving based on 4 factors: Compulsivity, Emotionality, Expectancy, Purposefulness. Each item asks about the respondent's feelings and thoughts about smoking marijuana as he or she is completing the questionnaire (i.e., right now). Each response is scored a number ranging from 1 (strongly disagree) to 7 (strongly agree) with higher scores indicating a greater level of craving. The calculation of each subscale is as follows: Compulsivity: Mean of items 2, 7, and 10; Emotionality: Mean of items 4, 6, and 9; Expectancy: Mean of items 5, 11, and 12; Purposefulness: Mean of items 1, 3, and 8 with the minimum possible score = 1 and the maximum possible score = 7 for any subscale. The mean and standard deviation of each subscale for each treatment condition will be reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"1.7"},{"groupId":"OG001","value":"3.0","spread":"1.8"},{"groupId":"OG002","value":"2.5","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"2.1"},{"groupId":"OG001","value":"3.5","spread":"1.8"},{"groupId":"OG002","value":"2.9","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"1.8"},{"groupId":"OG001","value":"4.6","spread":"1.8"},{"groupId":"OG002","value":"3.9","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"1.8"},{"groupId":"OG001","value":"4.8","spread":"2.2"},{"groupId":"OG002","value":"4.0","spread":"2.3"}]}]}]},{"type":"PRIMARY","title":"Mean Scores on the Modified Cigarette Evaluation Questionnaire (mCEQ)","description":"The modified Cigarette Evaluation Questionnaire (mCEQ) uses three multi-item subscales and two single items: \"Smoking Satisfaction\" (items 1, 2, and 12);\"Psychological Reward\" (items 4 through 8); \"Aversion\" (items 9 and 10);\"Enjoyment of Respiratory Tract Sensations\" (item 3); and \"Craving Reduction\"(item 11). Scores for each subscale are calculated as the mean of the individual item responses or the single item. Higher scores indicate greater intensity on that scale. Items are rated on a seven-point scale ranging from 1 (not at all) to 7 (extremely) and total scores are averaged across all items with a minimum average score of 1 and a maximum average score of 7. Higher scores indicate greater intensity of each smoking effect with, for example, greater satisfaction or psychological reward after smoking. The mean and standard deviation for each treatment condition will be reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"3.2"},{"groupId":"OG001","value":"3.1","spread":"3.5"},{"groupId":"OG002","value":"1.4","spread":"1.5"}]}]}]},{"type":"PRIMARY","title":"Mean Scores on the Positive Affect Negative Affect Schedule (PANAS)","description":"The Positive and Negative Affect Schedule (PANAS) is a brief scale is comprised of 20 items, with 10 items measuring positive affect (e.g., excited, inspired) and 10 items measuring negative affect (e.g., upset, afraid). Each item is rated on a five-point Likert Scale, ranging from 1 = Very Slightly or Not at all to 5 = Extremely, to measure the extent to which the affect has been experienced in a specified time frame and the final score is derived out of the sum of the ten items on both the positive and negative side. Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.9","spread":"11.6"},{"groupId":"OG001","value":"23.0","spread":"9.6"},{"groupId":"OG002","value":"25.8","spread":"11.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":"1.2"},{"groupId":"OG001","value":"11.4","spread":"3.1"},{"groupId":"OG002","value":"10.2","spread":"0.7"}]}]}]},{"type":"PRIMARY","title":"Mean Scores on the Minnesota Nicotine Withdrawal Scale (MNWS)","description":"The Minnesota Nicotine Withdrawal Scale is an 7-item self - report scale designed to measure the severity of craving and withdrawal symptoms experienced during smoking cessation. Each item is rated on a scale of 0 to 4 with 0=none,1= Slight, 2= Mild, 3= Moderate, and 4=Severe. Seven of the items are symptoms derived from the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) Tobacco Withdrawal diagnosis and are as follows: depression, insomnia, irritability/frustration/anger, anxiety/nervousness, difficulty concentrating, restlessness, increased appetite and at least five of seven items must have responses in order to generate a reliable score. The responses to each item are summed to produce a total withdrawal summary score with greater scores indicating a higher level of severity in nicotine withdrawal symptoms overall. The mean and standard deviation of each treatment condition will be reported with a minimum mean score of 0 and a maximum mean score of 4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.0"},{"groupId":"OG001","value":"1.2","spread":"1.2"},{"groupId":"OG002","value":"0.9","spread":"1.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":8},"commonTop":[]}}}